pdufa.bio

DURAVYU COMO

Page updated ·next FDA decision on the calendar ·Data as of Oct 11, 2026 9:31 PM ET

DURAVYU COMO is an EyePoint, Inc. program in diabetic macular edema. Its next catalyst is a Readout in Q4 2027. Every date links its source.

EYPT catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indication under review: diabetic macular edema. Sponsor: EyePoint, Inc. (EYPT). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Q4 2027EYPT

Specialist biotech funds holding EYPT, 13F for the quarter ended June 30, 2026

FundSharesValue at quarter endFiling
Cormorant Asset Management7,000,000$100.1 millionfiled August 14, 2026
OrbiMed Advisors1,069,147$15.3 millionfiled August 14, 2026

13F reports list long positions in common stock at quarter end, are due 45 days later, and show no short positions or later trades. Notes, warrants and other instruments are not counted as shares.

Questions

When is DURAVYU COMO's next FDA decision or readout?

The next tracked catalyst for DURAVYU COMO is a Readout in Q4 2027.

What happened at DURAVYU COMO's most recent FDA decision?

No FDA decision for DURAVYU COMO is in our archive yet.

What is DURAVYU COMO used for?

In our records DURAVYU COMO is under review or in development for diabetic macular edema.

Who makes DURAVYU COMO?

EyePoint, Inc. (EYPT).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings; every date on this page links its source.